...
首页> 外文期刊>Research and Reports in Urology >Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients with insomnia associated with lower urinary tract symptoms
【24h】

Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients with insomnia associated with lower urinary tract symptoms

机译:雷米替尼治疗下尿路症状伴失眠的疗效及抗炎作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objectives: This study was conducted to examine the therapeutic efficacy and anti-inflammatory effect of ramelteon in elderly patients with insomnia associated with lower urinary tract symptoms (LUTS), who visited our urology department.Methods: The study included 115 patients (102 men, 13 women) who scored ≥4 on the Athens Insomnia Scale and who wished to receive treatment. The assessment scales for therapeutic efficacy included the International Prostate Symptom Score (IPSS) for LUTS and the Insomnia Severity Index (ISI) for sleep disorders. The high-sensitivity C-reactive protein (hs-CRP) test was used to an objective assessment. The patients were treated with ramelteon (8 mg/day) for an average of 10 weeks and were then reexamined using the questionnaires and hs-CRP test to evaluate therapeutic efficacy.Results: IPSS total scores declined significantly from 11.39 ± 8.78 to 9.4 ± 7.72. ISI total scores improved significantly from 11.6 ± 5.2 to 9.2 ± 5.3 (P < 0.0001). The levels of hs-CRP decreased significantly from 0.082 (standard deviation [SD] upper limit, 0.222; SD lower limit, ?0.059) to 0.06 (SD upper limit, 0.152; SD lower limit, ?0.032). The ISI scores ≥ 10 (n = 51) showed a weak correlation with the hs-CRP levels.Conclusion: Ramelteon had a systemic anti-inflammatory effect and improved sleep disorders and LUTS, suggesting that it may be a useful treatment for patients with LUTS-associated insomnia.
机译:目的:本研究旨在探讨雷梅替尼对拜访我们泌尿科的老年下尿路症状伴有失眠症的老年患者的治疗效果和抗炎作用。方法:该研究共纳入115例患者(102例男性, 13名妇女)在雅典失眠量表上得分≥4并且希望接受治疗。治疗功效的评估量表包括LUTS的国际前列腺症状评分(IPSS)和睡眠障碍的失眠严重度指数(ISI)。高敏C反应蛋白(hs-CRP)测试用于客观评估。患者接受雷米替尼(8 mg /天)平均治疗10周,然后使用问卷调查表和hs-CRP测试进行重新检查以评估治疗效果。结果:IPSS总评分从11.39±8.78明显下降至9.4±7.72 。 ISI总分从11.6±5.2显着提高到9.2±5.3(P <0.0001)。 hs-CRP的水平从0.082(标准偏差[SD]上限,0.222; SD下限,≤0.059)显着降低到0.06(SD上限,0.152; SD下限,≤0.032)。 ISI评分≥10(n = 51)与hs-CRP水平相关性较弱。结论:雷美替尼具有全身性抗炎作用,改善了睡眠障碍和LUTS,这表明它可能是LUTS患者的一种有效治疗方法相关的失眠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号